U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06800729) titled 'A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects' on Jan. 23.
Brief Summary: A Single Center, Single Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Study Start Date: Jan., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: TIX100, an orally available inhibitor of thioredoxin-interacting protein
TIX100, an orally available inhibitor of thioredoxin-interacting protein
DRUG: Placebo
placebo
Recruitment Status: RECRUITING
Sponsor: TIXiMED, Inc.
Published by...